In clinical trials of CD19-targeted CAR-T adoptive therapy, although complete remission has been induced in 67%–93% of the patients with ALL, efforts to replicate such success to other malignancies have not achieved satisfactory outcomes yet, especially for solid tumors [60]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.